Headache News and Research

Latest Headache News and Research

Mosquito borne virus alert for Western Australia

There is a mosquito alert for people living and holidaying in northern and central WA after a high number of reports of encephalitis and Ross River virus. According to Department of Health entomologist Sue Harrington, it is confirmed that a Carnarvon resident has been diagnosed with the potentially fatal encephalitis while several other cases are currently being investigated.

12 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

New dengue test receives FDA marketing clearance

The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.

11 Apr 2011

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'

7 Apr 2011

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Alexion Pharmaceuticals, Inc. announced today that the company has submitted marketing applications to the U.S. Food and Drug Administration and the European Medicines Agency for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

7 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

New Pipeline Embolization Device receives FDA approval for treatment of brain aneurysms

The U.S. Food and Drug Administration today approved a new device that provides neurointerventional surgeons with another tool to treat brain aneurysms without performing open surgery.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Study finds substantial increase in pediatric CT in hospital emergency departments

Computed tomography examinations of children in hospital emergency departments increased substantially from 1995 to 2008, according to a new study published online and in the June print edition of Radiology. Researchers said the findings underscore the need for collaboration among medical professionals to ensure that pediatric CT is appropriately ordered, performed and interpreted.

5 Apr 2011

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist Pharmaceuticals, Inc. today announced that it has entered into a license agreement with Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., which includes a stipulation by the parties requesting dismissal of the lawsuit filed by Cubist in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application filed by TPM with the U.S. Food and Drug Administration for a generic version of CUBICIN.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.

4 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Eli Lilly and Company announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States. Axiron is a prescription medicine used to treat adult males that have low or no testosterone. Safety and efficacy of Axiron in males younger than 18 years of age have not been established.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Headache News and Research

Latest Headache News and Research

Mosquito borne virus alert for Western Australia

Gilenya can reduce risk of disability progression in patients with RRMS

New dengue test receives FDA marketing clearance

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

New Pipeline Embolization Device receives FDA approval for treatment of brain aneurysms

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

Study finds substantial increase in pediatric CT in hospital emergency departments

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Men who consume digoxin have 24% reduced risk of prostate cancer

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in